We are international

Millennium Pharmaceuticals announced promising new results for bortezomib (Velcade) in both previously untreated and relapsed multiple myeloma

Millennium announces promising results for Velcade

06.11.04   Results for patients with relapsed multiple myeloma
VELCADE(R) (Bortezomib) for Injection Data Show a Significant Improvement In Survival in Patients With Relapsed Multiple Myeloma- Risk of death in first year reduced by an estimated 30 percent in the VELCADE arm

06.11.04   Results for previously untreated multiple myeloma patients
VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients with Previously Untreated Multiple Myeloma